Cargando…

Physiologically based pharmacokinetic modeling to assess metabolic drug–drug interaction risks and inform the drug label for fedratinib

PURPOSE: Fedratinib (INREBIC(®)), a Janus kinase 2 inhibitor, is approved in the United States to treat patients with myelofibrosis. Fedratinib is not only a substrate of cytochrome P450 (CYP) enzymes, but also exhibits complex auto-inhibition, time-dependent inhibition, or mixed inhibition/inductio...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wu, Fan, Krishna, Gopal, Surapaneni, Sekhar
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7515950/ https://www.ncbi.nlm.nih.gov/pubmed/32886148 http://dx.doi.org/10.1007/s00280-020-04131-y

Ejemplares similares

Effect of fluconazole on the pharmacokinetics of a single dose of fedratinib in healthy adults
por: Chen, Yizhe, et al.
Publicado: (2022)

Population pharmacokinetics of fedratinib in patients with myelofibrosis, polycythemia vera, and essential thrombocythemia
por: Ogasawara, Ken, et al.
Publicado: (2019)

In vivo Pharmacokinetic Drug-Drug Interaction Studies Between Fedratinib and Antifungal Agents Based on a Newly Developed and Validated UPLC/MS-MS Method
por: Tang, Congrong, et al.
Publicado: (2021)

Physiologically‐Based Pharmacokinetic Model‐Informed Drug Development for Fenebrutinib: Understanding Complex Drug‐Drug Interactions
por: Chen, Yuan, et al.
Publicado: (2020)

Comprehensive Physiologically Based Pharmacokinetic Model to Assess Drug–Drug Interactions of Phenytoin
por: Rodriguez-Vera, Leyanis, et al.
Publicado: (2023)

Application of Physiologically Based Pharmacokinetic Modeling to Evaluate the Drug–Drug and Drug–Disease Interactions of Apatinib
por: Liu, Hongrui, et al.
Publicado: (2021)

Pharmacokinetic Drug–Drug Interactions and Herb–Drug Interactions
por: Choi, Min-Koo, et al.
Publicado: (2021)

Quantitative Assessment of Elagolix Enzyme-Transporter Interplay and Drug–Drug Interactions Using Physiologically Based Pharmacokinetic Modeling
por: Chiney, Manoj S., et al.
Publicado: (2019)

Quantitative Assessment of Levonorgestrel Binding Partner Interplay and Drug‐Drug Interactions Using Physiologically Based Pharmacokinetic Modeling
por: Cicali, Brian, et al.
Publicado: (2020)

Simulation and Prediction of the Drug‐Drug Interaction Potential of Naloxegol by Physiologically Based Pharmacokinetic Modeling
por: Zhou, D, et al.
Publicado: (2016)

Physiologically‐Based Pharmacokinetic Modeling to Support the Clinical Management of Drug–Drug Interactions With Bictegravir
por: Stader, Felix, et al.
Publicado: (2021)

Physiologically Based Pharmacokinetic Modeling of Rosuvastatin to Predict Transporter-Mediated Drug-Drug Interactions
por: Hanke, Nina, et al.
Publicado: (2021)

Evaluation of drug–drug interaction potential for pemigatinib using physiologically based pharmacokinetic modeling
por: Ji, Tao, et al.
Publicado: (2022)

Optimized Cocktail Phenotyping Study Protocol Using Physiological Based Pharmacokinetic Modeling and In silico Assessment of Metabolic Drug–Drug Interactions Involving Modafinil
por: Rowland, Angela, et al.
Publicado: (2016)

Clinical Utility of Fedratinib in Myelofibrosis
por: Waksal, Julian A, et al.
Publicado: (2021)

Drug Metabolism and Pharmacokinetics
Publicado: (2008)

Machine learning-based quantitative prediction of drug exposure in drug-drug interactions using drug label information
por: Jang, Ha Young, et al.
Publicado: (2022)

Application of physiologically based pharmacokinetic modeling in predicting drug–drug interactions for sarpogrelate hydrochloride in humans
por: Min, Jee Sun, et al.
Publicado: (2016)

Physiologically Based Pharmacokinetic Modeling Suggests Limited Drug–Drug Interaction Between Clopidogrel and Dasabuvir
por: Shebley, M, et al.
Publicado: (2017)

Physiologically Based Pharmacokinetic Models of Probenecid and Furosemide to Predict Transporter Mediated Drug-Drug Interactions
por: Britz, Hannah, et al.
Publicado: (2020)

Prediction of Drug–Drug Interaction Potential of Tegoprazan Using Physiologically Based Pharmacokinetic Modeling and Simulation
por: Yoon, Deok Yong, et al.
Publicado: (2021)

Physiologically Based Pharmacokinetic Modeling for Selumetinib to Evaluate Drug‐Drug Interactions and Pediatric Dose Regimens
por: Cohen‐Rabbie, Sarit, et al.
Publicado: (2021)

Potential drug-drug interaction of olverembatinib (HQP1351) using physiologically based pharmacokinetic models
por: Yu, Zhiheng, et al.
Publicado: (2022)

Physiologically‐Based Pharmacokinetic Model Development, Validation, and Application for Prediction of Eliglustat Drug–Drug Interactions
por: Sahasrabudhe, Siddhee A., et al.
Publicado: (2022)

A Physiologically Based Pharmacokinetic Model of Ketoconazole and Its Metabolites as Drug–Drug Interaction Perpetrators
por: Marok, Fatima Zahra, et al.
Publicado: (2023)

Physiologically-based pharmacokinetic modeling to predict drug-drug interactions of dabigatran etexilate and rivaroxaban in the Chinese older adults
por: Sia, Jie En Valerie, et al.
Publicado: (2023)

Physiologically based pharmacokinetic modeling of tacrolimus for food–drug and CYP3A drug–drug–gene interaction predictions
por: Loer, Helena Leonie Hanae, et al.
Publicado: (2023)

A systematic review on disease‐drug‐drug interactions with immunomodulating drugs: A critical appraisal of risk assessment and drug labelling
por: de Jong, Laura M., et al.
Publicado: (2022)

Using Nonexperts for Annotating Pharmacokinetic Drug-Drug Interaction Mentions in Product Labeling: A Feasibility Study
por: Hochheiser, Harry, et al.
Publicado: (2016)

Quantitative Prediction of Drug–Drug Interactions Involving Inhibitory Metabolites by Physiologically Based Pharmacokinetic Models: Is it Worth It?
por: Tod, M, et al.
Publicado: (2017)

Investigating Transporter‐Mediated Drug‐Drug Interactions Using a Physiologically Based Pharmacokinetic Model of Rosuvastatin
por: Wang, Q, et al.
Publicado: (2017)

Applications of Physiologically Based Pharmacokinetic Modeling of Rivaroxaban—Renal and Hepatic Impairment and Drug‐Drug Interaction Potential
por: Willmann, Stefan, et al.
Publicado: (2021)

Evaluation of the drug‐drug interaction potential of treosulfan using a physiologically‐based pharmacokinetic modelling approach
por: Schaller, Stephan, et al.
Publicado: (2021)

2535. Physiological-based pharmacokinetic analysis of drug–drug interactions between isavuconazole and vincristine in pediatric subjects
por: Choules, Mary P, et al.
Publicado: (2023)

A Physiologically Based Pharmacokinetic Model to Predict Potential Drug–Drug Interactions and Inform Dosing of Acumapimod, an Oral p38 MAPK Inhibitor
por: Agyemang, Alex, et al.
Publicado: (2020)

Application of Physiologically‐Based Pharmacokinetic Modeling to Predict Gastric pH‐Dependent Drug–Drug Interactions for Weak Base Drugs
por: Dong, Zhongqi, et al.
Publicado: (2020)

Assessing Consistency of Drug-Drug Interaction-Related Information Across Various Drug Information Resources
por: Shariff, Atiqulla, et al.
Publicado: (2021)

Drug–drug interaction prediction of ziritaxestat using a physiologically based enzyme and transporter pharmacokinetic network interaction model
por: Perrier, Jeremy, et al.
Publicado: (2023)

Pharmacokinetic drug-drug interaction and their implication in clinical management
por: Palleria, Caterina, et al.
Publicado: (2013)

Application of physiologically‐based pharmacokinetic model approach to predict pharmacokinetics and drug–drug interaction of rivaroxaban: A case study of rivaroxaban and carbamazepine
por: Ngo, Lien Thi, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_rkegu55q9obi3k4gnuqak87jk2